Monoclonal antibody

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Axys, Monoclonal antibody, US Foods, Interest, Crown Bioscience International, AbbVie, Quality of life, PDL, Rights, TKI, Research, NSCLC, Immunotherapy, Lung cancer, Forbes China Celebrity 100, Sale, Bayer Corporation, VEGF, Patient, Investment, EGFR, SMMT, Webcast, Knowledge, Entrepreneurship, PD-1, FDA, Woman, Summit, Collaboration, Phase, Compugen (company), Michelle, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Pfizer

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023.
  • The Collaboration and License Agreement with Akeso closed on January 17, 2023 after going effective following customary waiting periods.
  • In exchange for these rights, Summit committed to an upfront payment of $500 million, which was paid in two installments.
  • Operating cash outflow for the three month ended March 31, 2023 and 2022 was $13.1 million and $19.0 million, respectively.

Global Biopharmaceutical CMO & CRO Market is Expected to Reach $27.95 Billion by 2028: Players Include Toyobo, Samsung Biologics, Patheon, AbbVie and Binex - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 4, 2023
Biotechnology, Pharmaceutical, Health, Vaccine, Pressure, Partnership, Clinical trial, Investment, Monoclonal antibody, COVID-19, CMOS, MEA, Research, CMO, Inflammation, Confidentiality, Abbreviation, Neuroscience, Growth, Cardiology, RNAI, A-DNA, ChromeOS, Fine chemical

The abbreviations for contract research organisations and contract manufacturing companies in the pharmaceutical industry are biopharmaceutical CMO and CRO, respectively.

Key Points: 
  • The abbreviations for contract research organisations and contract manufacturing companies in the pharmaceutical industry are biopharmaceutical CMO and CRO, respectively.
  • Consumer demand for biopharmaceutical treatments has been a major driver of the biopharmaceutical industry's phenomenal growth.
  • Global Biopharmaceutical CMO and CRO Market is segmented based on the source, service, product, and region.
  • The biopharmaceutical CMO and CRO market is anticipated to grow quickly in the coming years as a result of these factors.

$15+ Billion Global Digital Biomanufacturing Market to 2035: Players Include GE Healthcare, Korber, Merck, Sartorius and Thermo Fisher Scientific

Retrieved on: 
Tuesday, May 2, 2023
DAS, Monoclonal antibody, Partnership, GE HealthCare, MES, Digital, Internet, Internet of things, COVID-19, Thermo Fisher Scientific, Type, USD, Organization, Machine learning, Risk, Dassault Systèmes, Disease, Fujifilm Diosynth Biotechnologies, Question 2, Biomanufacturing, Artificial intelligence, Growth, Merck, PAT, Research, Spacecraft, Sartorius, Automation, Sales, Cryptocurrency, Online shopping, Fine chemical, Pharmaceutical industry, 3D printing, Retail, Renewable energy, Software, Körber

Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.

Key Points: 
  • Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.
  • Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?
  • Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?
  • Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years.

Global Digital Biomanufacturing Market 2023 - 2025: Increasing Number of Approved Biologics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 27, 2023
Health, Biotechnology, DAS, Monoclonal antibody, Partnership, GE HealthCare, MES, Digital, Internet, Internet of things, COVID-19, Thermo Fisher Scientific, Question 1, Machine learning, Dassault Systèmes, Disease, Fujifilm Diosynth Biotechnologies, Question 2, Artificial intelligence, Growth, Merck, PAT, Spacecraft, Sartorius, Cryptocurrency, Online shopping, Fine chemical, Pharmaceutical industry, Software, Körber

Question 4: Which region has the highest market share in the global digital biomanufacturing market?

Key Points: 
  • Question 4: Which region has the highest market share in the global digital biomanufacturing market?
  • Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?
  • Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?
  • Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years.

Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis

Retrieved on: 
Tuesday, April 25, 2023
Vaccine, Goodwill, Monoclonal antibody, Therapy, Parasitism, Climate, PATH, Medical laboratory, RI, DC, Malaria, Research, Attention, ZERO, Doctor of Philosophy, Parliament, Pan-African Parliament, Death, Plasmodium falciparum, MD, Pathology, Brown University, SE, Artemisinin, Alpert Medical School, World Health Organization, Pharmaceutical industry, Southeast Asia, Ocean Biomedical

By targeting each of the three principle events in the parasite’s blood stage lifecycle, Ocean Biomedical believes this powerful approach will result in a highly effective and novel malaria vaccine.

Key Points: 
  • By targeting each of the three principle events in the parasite’s blood stage lifecycle, Ocean Biomedical believes this powerful approach will result in a highly effective and novel malaria vaccine.
  • The company is also working to develop the PfGARP component as a therapeutic target for a whole new class of anti-malarial drugs.
  • This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.
  • “I join the World Health Organization 2023 in saying, it is time for ZERO Malaria.”

Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Technology, Health, Pharmaceutical, Biometrics, Health Technology, Research, Software, Nanotechnology, Science, COVID-19, Maintenance, Antigen, Twist Bioscience, Astellas Pharma, Doctor of Philosophy, Martek Biosciences Corporation, Monoclonal antibody, Virology, SARS-CoV-2, Antibody, VHH, Charles, Twist, Autoimmune disease, Drug discovery, Silicon, Library, TSE, Pharmaceutical industry, Vaccine

“We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ability to meet the varying needs of our customers and support their success,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • “We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ability to meet the varying needs of our customers and support their success,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Twist will receive an upfront payment and will be eligible to receive annual maintenance fees and fees per product through payments associated with specific clinical and commercial milestones.
  • A VHH antibody, also known as a single domain antibody, is the antigen binding domain of the heavy chain, with three complementary determining regions (CDRs), or areas where antigens bind to the antibody.
  • The small size of the VHH antibodies allow them to access targets that traditional antibodies cannot, with tight binding affinity.

Gene Therapy Market Overview: Forecast Market Size, Major Driver, Key Trends And Largest Region - By The Business Research Company

Retrieved on: 
Monday, April 10, 2023
Monoclonal antibody, Cell death, Gene, Gene editing, Cancer, Research, TESSA, Death, Investment, Growth, American Cancer Society, Autoimmunity, Vaccine

LONDON, April 10, 2023 /PRNewswire/ -- As per The Business Research Company's Gene Therapy Global Market Report 2023, the global gene therapy market size will grow from $7.3 billion in 2022 to $9.4 billion in 2023 at a compound annual growth rate (CAGR) of more than 27%. The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.

Key Points: 
  • The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.
  • Increasing number of cancer cases is expected to drive the growth of the gene therapy market during the forecast period.
  • Cancer gene therapy is an emerging field using genetic material to modify cells in vitro or in vivo to help effect a cure.
  • As per the gene therapy market forecast, North America was the largest region in the gene therapy market, accounting for 44.6% of the global market in 2022.

Gene Therapy Market Overview: Forecast Market Size, Major Driver, Key Trends And Largest Region - By The Business Research Company

Retrieved on: 
Monday, April 10, 2023
Monoclonal antibody, Cell death, Gene, Gene editing, Cancer, Research, TESSA, Death, Investment, Growth, American Cancer Society, Autoimmunity, Vaccine

LONDON , April 10, 2023 /PRNewswire/ -- As per The Business Research Company's Gene Therapy Global Market Report 2023, the global gene therapy market size will grow from $7.3 billion in 2022 to $9.4 billion in 2023 at a compound annual growth rate (CAGR) of more than 27%. The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.

Key Points: 
  • The gene therapy market share is then expected to grow from $24 billion in 2027 at a CAGR of more than 26%.
  • Increasing number of cancer cases is expected to drive the growth of the gene therapy market during the forecast period.
  • Cancer gene therapy is an emerging field using genetic material to modify cells in vitro or in vivo to help effect a cure.
  • As per the gene therapy market forecast, North America was the largest region in the gene therapy market, accounting for 44.6% of the global market in 2022.

EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress

Retrieved on: 
Wednesday, March 22, 2023
Monoclonal antibody, Lymphoid leukemia, CD2, Immunology, Therapy, CD3, CD28, CD20, Neoplasm, Cancer, Research, Immunotherapy, Acute myeloid leukemia, CD8, Festival, Lymphocyte, EVOLVE, Pharmaceutical industry, Vaccine

BRANFORD, Conn., March 22, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data on EVOLVE™, the company’s novel costimulatory T cell engager platform, were featured in an oral presentation at the Festival of Biologics Immunotherapy World Congress. The presentation highlighted the potential of the company’s innovative integrated CD2 costimulatory strategy to overcome treatment limitations of current immunotherapies. Additionally, the company disclosed the first data for EVOLVE-105, its best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation.

Key Points: 
  • The presentation highlighted the potential of the company’s innovative integrated CD2 costimulatory strategy to overcome treatment limitations of current immunotherapies.
  • Additionally, the company disclosed the first data for EVOLVE-105, its best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation.
  • Moreover, they do not provide coordinated costimulatory receptor activation to overcome T cell dysfunction and drive more effective and longer lasting anti-tumor responses.
  • The Festival of Biologics presentation, entitled, “A novel costimulatory T cell engager platform engineered for the treatment of immune suppressive tumors,” included key new findings for the company’s EVOLVE platform and its growing costimulatory T cell engager portfolio.

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

Retrieved on: 
Monday, March 20, 2023
Bispecific monoclonal antibody, Pancreatic cancer, CD47, Macrophage, ADCC, ODD, Monoclonal antibody, RECIST, Pharmacokinetics, NK, Trial of the century, APC, Patient, ECOG, SAN, Cancer, ADCP, Neoplasm, Ageing, FDA, Therapy, Safety, Pharmaceutical industry

PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.

Key Points: 
  • PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.
  • The anti-CD47 arm of PT886 is highly differentiated and has demonstrated minimum binding to human red blood cells while maintains strong binding activity to CD47 on tumor cells.
  • "PT886 targets a validated tumor associated antigen in claudin 18.2 with enhanced anti-tumor activity and broadened tumor killing spectrum through a best-in-class anti-CD47 arm.
  • It is a product of Phanes' ingenious innovation in creative design of both novel therapeutic approaches and practical technologies," said Dr. Ming Wang, Founder and CEO of Phanes Therapeutics.